ClinicalTrials.gg
CompletedNCT03261427Updated Jul 10, 2019

Evaluate the Pharmacokinetic Characteristics and Safety/Tolerability of YNP-1807 Compared to Lyrica® After Oral Administration Adult Volunteers

A Phase 1 interventional study of Lyrica 150Mg Capsule and YNP-1807 330Mg Tablet in Healthy, sponsored by Yungjin Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-10.

Sponsored by Yungjin Pharm. Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The purpose of this trial to compare the pharmacokinetic characteristics of YNP-1807(Pregabalin 330mg) and Lyrica capsule(Pregabalin 150mg). YNP-1807 is made by Yungjin Pharm. Primary endpoints are AUClast and Cmax and secondary endpoints are AUCinf, Tmax, t1/2, Vd/f, CL/f.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Yungjin Pharm. Co., Ltd. is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19 years to 55 years healthy volunteers adult at screening visit
  • For male, weight is more than 55 kg, for female, weight is more than 50 kg.
  • (BMI) value : 18.5 to 25.0 kg/m2
  • If female, should be included one at least as following

    • menopausal(menstruation for 2 years minimum)
    • surgery infertility

Exclusion criteria

Exclusion Criteria:

  • Any history of drug overdose or dependence
  • Female who is pregnant or nursing
  • , ALT > *1.25
  • Total > ULN*1.5
  • CPK > ULN*1.5
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    YNP-1807 Tablet(Pregabalin 330mg)

    YNP-1807(Pregabalin 330mg), QD

    Drug: YNP-1807 330Mg Tablet

  • Active comparator
    Lyrica Capsule(Pregabalin 150mg)

    Lyrica Capsule(Pregabalin 150mg), BID

    Drug: Lyrica 150Mg Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Part I : AUClast of Pregabalin

    Time frame: 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  2. Part I : Cmax of Pregabalin

    Time frame: 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  3. Part II : AUCτ,ss of Pregabalin

    Time frame: Pre-dose, 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  4. Part II : Cmax,ss of Pregabalin

    Time frame: Pre-dose, 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

Secondary outcomes

  1. Part I : AUCinf of Pregabalin

    Time frame: 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  2. Part I : Tmax of Pregabalin

    Time frame: 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  3. Part I : t1/2 of Pregabalin

    Time frame: 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  4. Part I : Vd/F of Pregabalin

    Time frame: 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  5. Part I : CL/F of Pregabalin

    Time frame: 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  6. Part II : Cmin,ss of Pregabalin

    Time frame: Pre-dose, 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  7. Part II : AUClast,ss of Pregabalin

    Time frame: Pre-dose, 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  8. Part II : Tmax,ss of Pregabalin

    Time frame: Pre-dose, 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  9. Part II : t1/2 of Pregabalin

    Time frame: Pre-dose, 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  10. Part II : CLss/F of Pregabalin

    Time frame: Pre-dose, 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  11. Part II : Vdss/F of Pregabalin

    Time frame: Pre-dose, 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  12. Part II : accumulation ratio(Cmax) of Pregabalin

    Time frame: Pre-dose, 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

  13. Part II : accumulation ratio(AUCτ) of Pregabalin

    Time frame: Pre-dose, 0,1,2,3,4,5,6,7,8,10,12,16,20,24,36 hours

07

Study locations

1 site
  • Severance Hospital
    Seoul, Yonsei-ro Seodaemun-gu 120-752, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Oct 2017, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2017
First posted
Aug 25, 2017
StartActual
Sep 14, 2017
Primary completionActual
Oct 11, 2017
CompletionActual
Mar 29, 2018
Last update
Jul 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03261427
Lead sponsor
Yungjin Pharm. Co., Ltd.
Responsible party
Sponsor
First posted
Aug 25, 2017
Start date
Sep 14, 2017
Primary completion
Oct 11, 2017
Completion
Mar 29, 2018
Last update
Jul 10, 2019

Study contacts

MinSoo Park, MD,PhD
principal investigator · Severance Hospital, Seoul, Korea

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion